AngioDynamics, Inc. (ANGO)
| Market Cap | 456.42M +17.3% |
| Revenue (ttm) | 313.73M +10.7% |
| Net Income | -31.39M |
| EPS | -0.76 |
| Shares Out | 41.68M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 33,729 |
| Open | 10.96 |
| Previous Close | 11.03 |
| Day's Range | 10.92 - 11.09 |
| 52-Week Range | 8.36 - 13.99 |
| Beta | 0.37 |
| Analysts | Strong Buy |
| Price Target | 18.00 (+64.38%) |
| Earnings Date | Apr 2, 2026 |
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. The company’s thrombus management portfolio includes AlphaVac mechanical thrombectomy system, an emergent mechanical aspiration device tha... [Read more]
Financial Performance
In fiscal year 2025, AngioDynamics's revenue was $292.50 million, a decrease of -3.76% compared to the previous year's $303.91 million. Losses were -$33.99 million, -81.56% less than in 2024.
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for ANGO stock is "Strong Buy." The 12-month stock price target is $18.0, which is an increase of 64.38% from the latest price.
News
AngioDynamics announces two-year PRESERVE trial data
AngioDynamics (ANGO) announced two-year results from the PRESERVE pivotal trial demonstrating durable oncologic control and a sustained safety profile for the NanoKnife System in the focal ablation of...
AngioDynamics Announces Two-Year PRESERVE Trial Data Demonstrating Durable NanoKnife IRE System Outcomes in Intermediate-Risk Prostate Cancer
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: 25th Annual Needham Virtual Healthcare Conference
The company has transformed its portfolio, focusing on high-growth MedTech segments and innovative devices for cardiovascular and oncology markets. Strong financials, ongoing product innovation, and market expansion position it for sustained growth and margin improvement.
AngioDynamics initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of AngioDynamics (ANGO) with a Buy rating and $16 price target The firm sees an improved growth profile for the company due to its pivot to…
AngioDynamics price target lowered to $16 from $18 at Canaccord
Canaccord lowered the firm’s price target on AngioDynamics (ANGO) to $16 from $18 and keeps a Buy rating on the shares. The firm said they delivered a good FQ3 with…
AngioDynamics Earnings Call Transcript: Q3 2026
Third quarter revenue grew 8.9% year-over-year, led by MedTech segment strength and robust growth in Auryon, AlphaVac, and NanoKnife. Full-year guidance for net sales and adjusted EBITDA was raised for the third consecutive quarter, with strong cash and no debt.
Options Volatility and Implied Earnings Moves Today, April 02, 2026
Today, several major companies are expected to report earnings: Acuity Brands (AYI), AngioDynamics (ANGO), Lindsay (LNN). Ahead of earnings, TipRanks shows you the expected earnings move, which is bas...
AngioDynamics reports Q3 adjusted EPS (7c), consensus (11c)
Reports Q3 revenue $78.4M, consensus $76.77M. “We delivered a strong quarter, driven by continued execution across the organization, allowing us to deliver yet another quarter of profitable growth,” c...
AngioDynamics narrow FY26 EPS view to (30c)-(23c) from (33c)-(23c)
FY26 EPS consensus (29c). Raises FY26 revenue view to $313.5M-$315.5M from $312M-$314M, consensus $312.88M.
AngioDynamics Reports Fiscal Year 2026 Third Quarter Financial Results; Sustained Double-Digit Med Tech Growth Drives Continued Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Present at the 25th Annual Needham Virtual Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Report Fiscal 2026 Third Quarter Results on April 2, 2026
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Transcript: Leerink Global Healthcare Conference 2026
The business has transformed into a tech-focused med tech company, driving strong growth in cardiovascular and oncology platforms. Med Tech products are outperforming expectations, with Auryon and AlphaVac leading expansion, while NanoKnife is gaining traction in prostate cancer and BPH. Robust R&D and a growing sales force support continued momentum.
AngioDynamics to Present at the Leerink Partners Global Healthcare Conference
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics Expands Indications for the NanoKnife System Across Europe, Strengthening Multi-Organ Tumor Ablation Platform
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics and The PERT Consortium® Launch Investigator-Led Research Fund to Advance Pulmonary Embolism Care
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...
AngioDynamics to Convene Cardiovascular Leaders at Scientific Forum as Pipeline Continues to Advance
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment option...
AngioDynamics Transcript: 44th Annual J.P. Morgan Healthcare Conference
A science-driven transformation has positioned the company for strong growth, with MedTech now driving over 45% of revenue and expanding rapidly. Key products like Auryon, AlphaVac, and NanoKnife are gaining market share, while financial performance is improving with positive EBITDA and cash flow. Leadership transition is underway, but the outlook remains robust.
AngioDynamics Earnings Call Transcript: Q2 2026
Revenue grew 8.8% year-over-year, led by Med Tech and Auryon platform strength, with gross margin up 170 bps and adjusted EBITDA nearly doubling. Full-year guidance for revenue and EBITDA was raised, and key regulatory milestones were achieved in mechanical thrombectomy. Leadership transition was announced.
Options Volatility and Implied Earnings Moves Today, January 06, 2026
Today, several major companies are expected to report earnings: AAR (AIR), AngioDynamics (ANGO). Ahead of earnings, TipRanks shows you the expected earnings move, which is based on options prices. Man...
AngioDynamics says still expects to be cash flow positive for FY26
AngioDynamics (ANGO) ended fiscal 2026 second quarter with $41.6M in cash and cash equivalents, ahead of the company’s expectations. It continues to expect to be cash flow positive for the…
AngioDynamics reports Q2 adjusted EPS 0c, consensus (10c)
Reports Q2 revenue $79.4M, consensus $76.43M. “We delivered an excellent second quarter, with continued strong Med Tech growth driving our overall performance,” commented Jim Clemmer, President and Ch...
AngioDynamics backs FY26 adjusted EPS view (33c)-(23c), consensus (33c)
Raises FY26 revenue view to $312M-$314M from $308M-$313M, consensus $310.27M. Raises FY26 adjusted EBITDA view to $8M-$10M from $6M-$10M.
AngioDynamics says Jim Clemmer to retire during FY27 as CEO
The company announced that Jim Clemmer has informed the Board of Directors of his intention to retire from the company upon the appointment of a successor, which is anticipated to…
AngioDynamics Reports Fiscal Year 2026 Second Quarter Financial Results; Continued Double Digit Med Tech Growth Drives Increased Profitability
LATHAM, N.Y.--(BUSINESS WIRE)--AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expand...